What is the role of immunotherapy in the treatment of amyloidosis?

Updated: May 09, 2019
  • Author: Robert O Holmes, Jr, DO; Chief Editor: Herbert S Diamond, MD  more...
  • Print


Aβ immunotherapies have shown some promise in the treatment of Alzheimer disease. Agents with great potential include the passive monoclonal antibodies bapineuzumab [50] and solanezumab. [104] However, both of these humanized monoclonal antibodies have failed to provide meaningful cognitive changes in clinical trials. [105] Further studies using this strategy are ongoing.

Several other monoclonal antibodies to target Aβ deposition include “PF-04360365 (ponezumab), which targets the free C-terminus of Aβ, and specifically Aβ34–41; MABT5102A, which binds to Aβ monomers, oligomers, and fibrils with equally high affinity; GSK933776A, which, similar to bapineuzumab, targets the N-terminal sequence of Aβ; BAN2401, which targets Aβ protofibrils; and gantenerumab, which targets the N-terminus and central portion of Aβ.” [106]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!